Increased prolactin response to buspirone in Chronic Fatigue Syndrome (CFS)

We studied the endocrine and subjective responses that
followed acute administration of the 5-HT1A receptor agonist
buspirone (0.5 mg/kg orally) in 11 male patients with chronic
fatigue syndrome (CFS) and a group of matched healthy
controls. Patients with CFS had significantly higher plasma
prolactin concentrations and experienced more nausea in
response to buspirone than did controls. However, the growth
hormone response to buspirone did not distinguish CFS
patients from controls. Our data question whether the
enhancement of buspirone-induced prolactin release in CFS is
a consequence of increased sensitivity of post-synaptic
5-HT1A receptors. It is possible that the increased prolactin
response to buspirone in CFS could reflect changes in dopamine

Sharpe M, Clements A, Hawton K, Young AH, Sargent P, Cowen PJ

1 Star2 Stars3 Stars4 Stars5 Stars (21 votes, average: 2.50 out of 5)

Leave a Reply